82 FR 16401 - DaVita, Inc., RV Management Corp., Renal Ventures Partners, LLC, Renal Ventures Limited, LLC, and Renal Ventures Management, LLC; Analysis To Aid Public Comment
FEDERAL TRADE COMMISSION Federal Register Volume 82, Issue 63 (April 4, 2017)
Federal Register Volume 82, Issue 63 (April 4, 2017)
| Page Range | 16401-16403 | |
| FR Document | 2017-06556 |
[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)] [Notices] [Pages 16401-16403] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-06556] [[Page 16401]] ======================================================================= ----------------------------------------------------------------------- FEDERAL TRADE COMMISSION [File No. 151 0204] DaVita, Inc., RV Management Corp., Renal Ventures Partners, LLC, Renal Ventures Limited, LLC, and Renal Ventures Management, LLC; Analysis To Aid Public Comment AGENCY: Federal Trade Commission. ACTION: Proposed consent agreement. ----------------------------------------------------------------------- SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the complaint and the terms of the consent order-- embodied in the consent agreement--that would settle these allegations. DATES: Comments must be received on or before April 27, 2017. ADDRESSES: Interested parties may file a comment at https://ftcpublic.commentworks.com/ftc/davitarenalconsent online or on paper, by following the instructions in the Request for Comment part of the SUPPLEMENTARY INFORMATION section below. Write ``In the Matter of DaVita, Inc., RV Management Corp., Renal Ventures Partners, LLC, Renal Ventures Limited, LLC, and Renal Ventures Management, LLC., File No. 151-0204'' on your comment and file your comment online at https://ftcpublic.commentworks.com/ftc/davitarenalconsent by following the instructions on the web-based form. If you prefer to file your comment on paper, write ``In the Matter of DaVita, Inc., RV Management Corp., Renal Ventures Partners, LLC, Renal Ventures Limited, LLC, and Renal Ventures Management, LLC., File No. 151-0204'' on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC 20024. FOR FURTHER INFORMATION CONTACT: Lisa DeMarchi Sleigh (202-326-2535), Bureau of Competition, 600 Pennsylvania Avenue NW., Washington, DC 20580. SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing consent orders to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for March 28, 2017), on the World Wide Web, at http://www.ftc.gov/os/actions.shtm. You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before April 27, 2017. Write ``In the Matter of DaVita, Inc., RV Management Corp., Renal Ventures Partners, LLC, Renal Ventures Limited, LLC, and Renal Ventures Management, LLC., File No. 151-0204'' on your comment. Your comment-- including your name and your state--will be placed on the public record of this proceeding, including, to the extent practicable, on the public Commission Web site, at https://www.ftc.gov/policy/public-comments. As a matter of discretion, the Commission tries to remove individuals' home contact information from comments before placing them on the Commission Web site. Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, like anyone's Social Security number, date of birth, driver's license number or other state identification number or foreign country equivalent, passport number, financial account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, like medical records or other individually identifiable health information. In addition, do not include any ``[t]rade secret or any commercial or financial information which . . . is privileged or confidential,'' as discussed in Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names. If you want the Commission to give your comment confidential treatment, you must file it in paper form, with a request for confidential treatment, and you have to follow the procedure explained in FTC Rule 4.9(c), 16 CFR 4.9(c).\1\ Your comment will be kept confidential only if the FTC General Counsel, in his or her sole discretion, grants your request in accordance with the law and the public interest. --------------------------------------------------------------------------- \1\ In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c), 16 CFR 4.9(c). --------------------------------------------------------------------------- Postal mail addressed to the Commission is subject to delay due to heightened security screening. As a result, we encourage you to submit your comments online. To make sure that the Commission considers your online comment, you must file it at https://ftcpublic.commentworks.com/ftc/davitarenalconsent by following the instructions on the web-based form. If this Notice appears at http://www.regulations.gov/#!home, you also may file a comment through that Web site. If you file your comment on paper, write ``In the Matter of DaVita, Inc., RV Management Corp., Renal Ventures Partners, LLC, Renal Ventures Limited, LLC, and Renal Ventures Management, LLC., File No. 151-0204'' on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC. If possible, submit your paper comment to the Commission by courier or overnight service. Visit the Commission Web site at http://www.ftc.gov to read this Notice and the news release describing it. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before April 27, 2017. You can find more information, including routine uses permitted by the Privacy Act, in the Commission's privacy policy, at http://www.ftc.gov/ftc/privacy.htm. Analysis of Agreement Containing Consent Order To Aid Public Comment The Federal Trade Commission (``Commission'') has accepted, subject to final approval, an Agreement Containing Consent Order (``Consent Agreement'') from DaVita, Inc. (``DaVita''). The purpose of the Consent [[Page 16402]] Agreement is to remedy the anticompetitive effects resulting from DaVita's purchase of Renal Ventures Management, LLC from Renal Ventures Limited, LLC, which is owned by RV Management Corp. and Renal Ventures Partners, LLC (together, ``Renal Ventures''). Under the terms of the Consent Agreement, DaVita is required to divest seven dialysis clinics in seven markets across the United States. The Consent Agreement has been placed on the public record for 30 days to solicit comments from interested persons. Comments received during this period will become part of the public record. After 30 days, the Commission will again review the Consent Agreement and the comments received, and will decide whether it should withdraw from the Consent Agreement, modify it, or make final the Decision and Order (``Order''). The Transaction Pursuant to an agreement dated August 17, 2015, DaVita proposes to acquire all issued and outstanding equity interests in Renal Ventures in a transaction valued at approximately $358 million. The Commission's Complaint alleges that the proposed acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. 45, by substantially lessening competition for the provision of outpatient dialysis services in seven markets. The Respondents Headquartered in Denver, Colorado, DaVita is the second-largest provider of outpatient dialysis services in the United States. DaVita operates or manages 2,251 outpatient dialysis clinics in forty-six states and the District of Columbia at which approximately 180,000 end stage renal disease (``ESRD'') patients receive treatment. In 2015, DaVita's revenues were approximately $13.8 billion. Renal Ventures, headquartered in Lakewood, Colorado, is a privately held company and the seventh-largest provider of outpatient dialysis services in the United States. Renal Ventures operates thirty-six dialysis centers, providing dialysis services to approximately 2,300 patients in six states. In 2015, Renal Ventures' revenues were approximately $161 million. The Relevant Product and Structure of the Markets Outpatient dialysis services is the relevant product market in which to assess the effects of the proposed transaction. For patients suffering from ESRD, dialysis treatments are a life-sustaining therapy that replaces the function of the kidneys by removing toxins and excess fluid from the blood. Kidney transplantation is the only alternative to dialysis for ESRD patients. However, the wait-time for donor kidneys-- during which ESRD patients must receive dialysis treatments--can exceed five years. Additionally, many ESRD patients are not viable transplant candidates. As a result, ESRD patients have no alternative to dialysis treatments. Unless hospitalized, ESRD patients must obtain dialysis treatments from outpatient dialysis clinics. Because most ESRD patients receive outpatient dialysis treatment three times per week in sessions lasting between three and five hours the relevant geographic markets are local and limited by the travel distance from patients' homes. ESRD patients are often very ill and suffer from multiple health problems, making travel further than thirty miles or thirty minutes very difficult. As a result, competition among dialysis clinics occurs at a local level, corresponding to metropolitan areas or subsets thereof. The exact contours of each market vary depending on traffic patterns, local geography, and the patients' proximity to the nearest center. Competitive Effects of the Acquisition Each of the seven geographic markets identified in the Complaint is highly concentrated. In each of the affected markets, the proposed acquisition would cause the number of providers to drop from three to two or cause a merger to monopoly, and the post-acquisition HHI levels to exceed 5,000, and in the three-to-two provider markets, changes in their HHIs greater than 200. The high post-acquisition concentration levels, along with the elimination of the head-to-head competition between DaVita and Renal Ventures, suggest the proposed combination likely would result in higher prices for outpatient dialysis services in each geographic market. In addition, market participants compete for patients on a number of quality measures--including quality of facilities, wait times, operating hours, and location. The proposed combination likely also would result in diminished service and quality for patients in each market. Entry Entry into the outpatient dialysis services markets identified in the Commission's Complaint is not likely to occur in a timely manner at a level sufficient to deter or counteract the likely anticompetitive effects of the proposed transaction. By law, each dialysis clinic must have a nephrologist medical director, and most dialysis clinics have long-term (seven to ten year) contracts with nephrologist medical directors, that also include non-competes. As a practical matter, medical directors also serve as the primary source of referrals and are essential to a clinic's success. The relative shortage and lack of available nephrologists, particularly those with an established referral stream, is a significant barrier to entry into each of the relevant markets. These obstacles make entry in the affected markets more challenging and less likely to avert the anticompetitive effects of the transaction. The Consent Agreement The Consent Agreement remedies the proposed acquisition's anticompetitive effects in seven markets where both DaVita and Renal Ventures operate dialysis clinics by requiring DaVita to divest seven outpatient dialysis clinics to PDA-GMF Holdco LLP, a joint venture between Physicians Dialysis and GMF Capital LLC (``PDA''). Physicians Dialysis has been in business since 1990 and currently operates several outpatient dialysis clinics. The Commission is satisfied that PDA is a qualified acquirer of the divested assets. As part of the divestitures, DaVita is required to obtain the agreement of the medical director affiliated with each divested clinic to continue providing physician services after the transfer of ownership to the buyer. Similarly, the Consent Agreement requires DaVita to obtain the consent of all lessors necessary to assign the leases for the real property associated with the divested clinics to the buyer. These provisions ensure that the buyer will have the assets necessary to operate the divested clinics in a competitive manner. The Consent Agreement contains several additional provisions designed to help ensure the continued competitiveness of the divested clinics. First, the Consent Agreement provides the buyer with the opportunity to interview and hire employees affiliated with the divested clinics and prevents DaVita from offering these employees incentives to decline the buyer's offer of employment. This helps ensure the buyer has access to patient care and supervisory staff familiar with the clinics' patients and the local physicians. Second, the Consent Agreement prevents DaVita from contracting with the medical directors affiliated with the divested clinics for three years, to prevent DaVita from [[Page 16403]] potentially limiting the competitiveness of the divested clinics. Third, to ensure continuity of patient care and records as the buyer implements its quality care, billing, and supply systems, the Consent Agreement requires DaVita to provide transition services for a period up to twenty-four months. Firewalls and confidentiality agreements will prevent the exchange of competitively sensitive information. Fourth, the Consent Agreement requires DaVita to provide the buyer with a license to Renal Ventures' policies, procedures, and medical protocols, as well as the option to obtain and use DaVita's medical protocols, policies, and procedures, to help with continuity of care for the divested clinics' patients. The Consent Agreement requires DaVita to provide notice to the Commission prior to any acquisitions of dialysis clinics in the markets addressed by the Consent Agreement to ensure that subsequent acquisitions do not adversely impact competition in those markets or undermine the remedial goals of the proposed order. Finally, the Consent Agreement allows the Commission to appoint a monitor to oversee DaVita's compliance with the Consent Agreement. The purpose of this analysis is to facilitate public comment on the Consent Agreement, and it is not intended to constitute an official interpretation of the proposed Decision and Order, or to modify its terms in any way. By direction of the Commission. Donald S. Clark, Secretary. [FR Doc. 2017-06556 Filed 4-3-17; 8:45 am] BILLING CODE 6750-01-P
![Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices 16401
FEDERAL TRADE COMMISSION consent agreement containing consent 4.9(c).1 Your comment will be kept
orders to cease and desist, having been confidential only if the FTC General
[File No. 151 0204]
filed with and accepted, subject to final Counsel, in his or her sole discretion,
DaVita, Inc., RV Management Corp., approval, by the Commission, has been grants your request in accordance with
Renal Ventures Partners, LLC, Renal placed on the public record for a period the law and the public interest.
Ventures Limited, LLC, and Renal of thirty (30) days. The following Postal mail addressed to the
Ventures Management, LLC; Analysis Analysis to Aid Public Comment Commission is subject to delay due to
To Aid Public Comment describes the terms of the consent heightened security screening. As a
agreement, and the allegations in the result, we encourage you to submit your
AGENCY: Federal Trade Commission. complaint. An electronic copy of the comments online. To make sure that the
ACTION: Proposed consent agreement. full text of the consent agreement Commission considers your online
package can be obtained from the FTC comment, you must file it at https://
SUMMARY: The consent agreement in this Home Page (for March 28, 2017), on the ftcpublic.commentworks.com/ftc/
matter settles alleged violations of davitarenalconsent by following the
World Wide Web, at http://www.ftc.gov/
federal law prohibiting unfair methods instructions on the web-based form. If
os/actions.shtm.
of competition. The attached Analysis to this Notice appears at http://
You can file a comment online or on
Aid Public Comment describes both the www.regulations.gov/#!home, you also
paper. For the Commission to consider
allegations in the complaint and the may file a comment through that Web
your comment, we must receive it on or
terms of the consent order—embodied site.
before April 27, 2017. Write ‘‘In the
in the consent agreement—that would If you file your comment on paper,
Matter of DaVita, Inc., RV Management
settle these allegations. write ‘‘In the Matter of DaVita, Inc., RV
Corp., Renal Ventures Partners, LLC,
DATES: Comments must be received on Renal Ventures Limited, LLC, and Renal Management Corp., Renal Ventures
or before April 27, 2017. Ventures Management, LLC., File No. Partners, LLC, Renal Ventures Limited,
ADDRESSES: Interested parties may file a 151–0204’’ on your comment. Your LLC, and Renal Ventures Management,
comment at https:// comment—including your name and LLC., File No. 151–0204’’ on your
ftcpublic.commentworks.com/ftc/ your state—will be placed on the public comment and on the envelope, and mail
davitarenalconsent online or on paper, record of this proceeding, including, to your comment to the following address:
by following the instructions in the the extent practicable, on the public Federal Trade Commission, Office of the
Request for Comment part of the Commission Web site, at https:// Secretary, 600 Pennsylvania Avenue
SUPPLEMENTARY INFORMATION section www.ftc.gov/policy/public-comments. NW., Suite CC–5610 (Annex D),
below. Write ‘‘In the Matter of DaVita, As a matter of discretion, the Washington, DC 20580, or deliver your
Inc., RV Management Corp., Renal Commission tries to remove individuals’ comment to the following address:
Ventures Partners, LLC, Renal Ventures Federal Trade Commission, Office of the
home contact information from
Limited, LLC, and Renal Ventures Secretary, Constitution Center, 400 7th
comments before placing them on the
Management, LLC., File No. 151–0204’’ Street SW., 5th Floor, Suite 5610
Commission Web site.
on your comment and file your (Annex D), Washington, DC. If possible,
Because your comment will be made
comment online at https:// submit your paper comment to the
public, you are solely responsible for
ftcpublic.commentworks.com/ftc/ Commission by courier or overnight
making sure that your comment does
davitarenalconsent by following the service.
not include any sensitive personal
Visit the Commission Web site at
instructions on the web-based form. If information, like anyone’s Social
http://www.ftc.gov to read this Notice
you prefer to file your comment on Security number, date of birth, driver’s
and the news release describing it. The
paper, write ‘‘In the Matter of DaVita, license number or other state
FTC Act and other laws that the
Inc., RV Management Corp., Renal identification number or foreign country
Commission administers permit the
Ventures Partners, LLC, Renal Ventures equivalent, passport number, financial
collection of public comments to
Limited, LLC, and Renal Ventures account number, or credit or debit card
consider and use in this proceeding as
Management, LLC., File No. 151–0204’’ number. You are also solely responsible
appropriate. The Commission will
on your comment and on the envelope, for making sure that your comment does
consider all timely and responsive
and mail your comment to the following not include any sensitive health
public comments that it receives on or
address: Federal Trade Commission, information, like medical records or
before April 27, 2017. You can find
Office of the Secretary, 600 other individually identifiable health
more information, including routine
Pennsylvania Avenue NW., Suite CC– information. In addition, do not include
uses permitted by the Privacy Act, in
5610 (Annex D), Washington, DC 20580, any ‘‘[t]rade secret or any commercial or
the Commission’s privacy policy, at
or deliver your comment to the financial information which . . . is
http://www.ftc.gov/ftc/privacy.htm.
following address: Federal Trade privileged or confidential,’’ as discussed
Commission, Office of the Secretary, in Section 6(f) of the FTC Act, 15 U.S.C. Analysis of Agreement Containing
Constitution Center, 400 7th Street SW., 46(f), and FTC Rule 4.10(a)(2), 16 CFR Consent Order To Aid Public Comment
5th Floor, Suite 5610 (Annex D), 4.10(a)(2). In particular, do not include The Federal Trade Commission
Washington, DC 20024. competitively sensitive information (‘‘Commission’’) has accepted, subject to
FOR FURTHER INFORMATION CONTACT: Lisa such as costs, sales statistics, final approval, an Agreement
DeMarchi Sleigh (202–326–2535), inventories, formulas, patterns, devices, Containing Consent Order (‘‘Consent
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Bureau of Competition, 600 manufacturing processes, or customer Agreement’’) from DaVita, Inc.
Pennsylvania Avenue NW., Washington, names. (‘‘DaVita’’). The purpose of the Consent
DC 20580. If you want the Commission to give
SUPPLEMENTARY INFORMATION: Pursuant your comment confidential treatment, 1 In particular, the written request for confidential
to Section 6(f) of the Federal Trade you must file it in paper form, with a treatment that accompanies the comment must
request for confidential treatment, and include the factual and legal basis for the request,
Commission Act, 15 U.S.C. 46(f), and and must identify the specific portions of the
FTC Rule 2.34, 16 CFR 2.34, notice is you have to follow the procedure comment to be withheld from the public record. See
hereby given that the above-captioned explained in FTC Rule 4.9(c), 16 CFR FTC Rule 4.9(c), 16 CFR 4.9(c).
VerDate Sep<11>2014 16:21 Apr 03, 2017 Jkt 241001 PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 E:\FR\FM\04APN1.SGM 04APN1](https://thefederalregister.org/doc/82_FR_16464/page/1.svg)
![Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices 16403
potentially limiting the competitiveness Relief (PEPFAR); GH17–003, (OMB) for review and approval in
of the divested clinics. Third, to ensure Conducting Public Health Research in accordance with the Paperwork
continuity of patient care and records as South Africa; and GH17–004, Reduction Act of 1995. The notice for
the buyer implements its quality care, Conducting Public Health Research the proposed information collection is
billing, and supply systems, the Consent Activities in Egypt. published to obtain comments from the
Agreement requires DaVita to provide Times and Dates: 9:00 a.m.–2:00 p.m., public and affected agencies.
transition services for a period up to EDT, April 25, 2017 (Closed), 9:00 a.m.– Written comments and suggestions
twenty-four months. Firewalls and 2:00 p.m., EDT, April 26, 2017 (Closed). from the public and affected agencies
confidentiality agreements will prevent Place: Teleconference. concerning the proposed collection of
the exchange of competitively sensitive Status: The meeting will be closed to information are encouraged. Your
information. Fourth, the Consent the public in accordance with comments should address any of the
Agreement requires DaVita to provide provisions set forth in Section following: (a) Evaluate whether the
the buyer with a license to Renal 552b(c)(4) and (6), Title 5 U.S.C., and proposed collection of information is
Ventures’ policies, procedures, and the Determination of the Director, necessary for the proper performance of
medical protocols, as well as the option Management Analysis and Services the functions of the agency, including
to obtain and use DaVita’s medical Office, CDC, pursuant to Public Law 92– whether the information will have
protocols, policies, and procedures, to 463. practical utility; (b) Evaluate the
help with continuity of care for the Matters for Discussion: The meeting accuracy of the agencies estimate of the
divested clinics’ patients. will include the initial review, burden of the proposed collection of
The Consent Agreement requires discussion, and evaluation of information, including the validity of
DaVita to provide notice to the applications received in response to the methodology and assumptions used;
Commission prior to any acquisitions of ‘‘Program Development and Research to (c) Enhance the quality, utility, and
dialysis clinics in the markets addressed Establish and Evaluate Innovative and clarity of the information to be
by the Consent Agreement to ensure that Emerging Best Practices in Clinical and collected; (d) Minimize the burden of
subsequent acquisitions do not Community Services through the the collection of information on those
adversely impact competition in those President’s Emergency Plan for AIDS who are to respond, including through
markets or undermine the remedial Relief (PEPFAR), FOA GH17–002; the use of appropriate automated,
goals of the proposed order. Finally, the ‘‘Conducting Public Health Research in electronic, mechanical, or other
Consent Agreement allows the South Africa’’, FOA GH17–003,; and technological collection techniques or
Commission to appoint a monitor to ‘‘Conducting Public Health Research other forms of information technology,
oversee DaVita’s compliance with the Activities in Egypt’’, FOA GH17–004. e.g., permitting electronic submission of
Consent Agreement. Contact Person for More Information: responses; and (e) Assess information
The purpose of this analysis is to collection costs.
Hylan Shoob, Scientific Review Officer,
facilitate public comment on the To request additional information on
Center for Global Health (CGH) Science
Consent Agreement, and it is not the proposed project or to obtain a copy
Office, CGH, CDC, 1600 Clifton Road,
intended to constitute an official of the information collection plan and
NE., Mailstop D–69, Atlanta, Georgia
interpretation of the proposed Decision instruments, call (404) 639–7570 or
30033, Telephone: (404) 639–4796.
and Order, or to modify its terms in any send an email to omb@cdc.gov. Written
The Director, Management Analysis
way. comments and/or suggestions regarding
and Services Office, has been delegated
By direction of the Commission. the authority to sign Federal Register the items contained in this notice
Donald S. Clark, notices pertaining to announcements of should be directed to the Attention:
Secretary. meetings and other committee CDC Desk Officer, Office of Management
[FR Doc. 2017–06556 Filed 4–3–17; 8:45 am] management activities, for both the and Budget, Washington, DC 20503 or
Centers for Disease Control and by fax to (202) 395–5806. Written
BILLING CODE 6750–01–P
Prevention and the Agency for Toxic comments should be received within 30
Substances and Disease Registry. days of this notice.
DEPARTMENT OF HEALTH AND Elaine L. Baker,
Proposed Project
HUMAN SERVICES Director, Management Analysis and Services Mobile Messaging Intervention to
Office Centers for Disease Control and Present New HIV Prevention Options for
Centers for Disease Control and
Prevention. Men Who have Sex with Men (MSM)
Prevention
[FR Doc. 2017–06537 Filed 4–3–17; 8:45 am] Study—New—National Center for HIV/
Disease, Disability, and Injury BILLING CODE 4163–18–P AIDS, Viral Hepatitis, STD, and TB
Prevention and Control Special Prevention (NCHHSTP), Centers for
Emphasis Panel (SEP): Initial Review Disease Control and Prevention (CDC).
DEPARTMENT OF HEALTH AND Background and Brief Description
In accordance with Section 10(a)(2) of HUMAN SERVICES
the Federal Advisory Committee Act Public health approaches to HIV
(Pub. L. 92–463), the Centers for Disease Centers for Disease Control and prevention and control are increasingly
Control and Prevention (CDC) Prevention complex for men who have sex with
announces a meeting for the initial men (MSM), a population with a
asabaliauskas on DSK3SPTVN1PROD with NOTICES
[30Day–17–17AX] disproportionately high burden of HIV
review of applications in response to
Funding Opportunity Announcement Agency Forms Undergoing Paperwork infection. In addition to the established
(FOA) GH17–002, Program Reduction Act Review biomedical treatments for HIV-positive
Development and Research to Establish MSM, and behavioral strategies to
and Evaluate Innovative and Emerging The Centers for Disease Control and reduce the risk of transmitting or
Best Practices in Clinical and Prevention (CDC) has submitted the contracting HIV, current
Community Services through the following information collection request recommendations incorporate the
President’s Emergency Plan for AIDS to the Office of Management and Budget breakthrough biomedical risk reduction
VerDate Sep<11>2014 16:21 Apr 03, 2017 Jkt 241001 PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 E:\FR\FM\04APN1.SGM 04APN1](https://thefederalregister.org/doc/82_FR_16464/page/3.svg)
Document Created: 2017-04-03 23:53:21
Document Modified: 2017-04-03 23:53:21
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Proposed consent agreement. | |
| Dates | Comments must be received on or before April 27, 2017. | |
| Contact | Lisa DeMarchi Sleigh (202-326-2535), Bureau of Competition, 600 Pennsylvania Avenue NW., Washington, DC 20580. | |
| FR Citation | 82 FR 16401 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR